{"url":"https://lda.senate.gov/api/v1/filings/6f393ffc-2b2e-49a9-a9bb-79665bbc2e69/","filing_uuid":"6f393ffc-2b2e-49a9-a9bb-79665bbc2e69","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2025,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/6f393ffc-2b2e-49a9-a9bb-79665bbc2e69/print/","filing_document_content_type":"text/html","income":"15000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Kathleen Jaeger","dt_posted":"2025-09-21T16:05:29-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"74 Windy Hollow Court","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Great Falls","registrant_state":"VA","registrant_zip":"22066","registrant":{"id":401108536,"url":"https://lda.senate.gov/api/v1/registrants/401108536/","house_registrant_id":56512,"name":"MEDSECUREAN.COM","description":null,"address_1":"74 Windy Hollow Court","address_2":null,"address_3":null,"address_4":null,"city":"Great Falls","state":"VA","state_display":"Virginia","zip":"22066","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"KATHLEEN JAEGER","contact_telephone":"+1 703-424-8049","dt_updated":"2026-07-13T16:39:36.966870-04:00"},"client":{"id":60141,"url":"https://lda.senate.gov/api/v1/clients/60141/","client_id":60141,"name":"INDIAN PHARMACEUTICAL ALLIANCE(FORMERLY INDIAN PHARMACEUTICAL ASSOCIATION)","general_description":"DeRisk Affordable Medicine Supply Chain; seeking Partnership with US Government & Allies","client_government_entity":null,"client_self_select":false,"state":null,"state_display":null,"country":"IN","country_display":"India","ppb_state":"VA","ppb_state_display":"Virginia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2024-02-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"The Indian Pharmaceutical Alliance (IPA) is dedicated to ensuring a level playing field in the U.S. pharmaceutical market and upholding the principles of the U.S. Hatch-Waxman Act to balance innovation with access. IPA members supply nearly 50% of Medicare Prescriptions, and of the top 10 U.S. therapeutic categories, the companies supply more than half of the prescriptions for 5 of the top 10 categories-ranging up to 60%. IPA members seek to explore U.S. - India supply chain resiliency partnership, and address affordable medicine sustainability reform measures. IPA actively supports targeted reforms to enhance the sustainability of the generic drug industry. Specifically, IPA advocates for substantial reforms of Pharmacy Benefit Managers (PBMs) and Group Purchasing Organizations (GPOs) to ensure transparent pricing and fair market practices that benefit consumers. Additionally, IPA champions efforts to close loopholes in the Hatch-Waxman Act that delay generic drug entry, facilitating timely access to affordable medications. These reforms are crucial for maintaining industry sustainability, reducing healthcare costs, and ensuring that effective, affordable treatment options remain accessible to all Americans. IPAs efforts underscore its pivotal role in promoting a healthy future for all Americans through enhanced access to affordable medicine and a robust, enduring pharmaceutical industry.","foreign_entity_issues":"The Indian Pharmaceutical Alliance (IPA) members play a critical role in the U.S. healthcare system, supplying nearly 50% of Medicare prescriptions. In the top 10 U.S. therapeutic categories, IPA companies provide more than half of the prescriptions for 5 of these categories, with involvement in some categories up to 60%. These statistics underscore the significant impact IPA has on making essential medications accessible and affordable. Building on this foundation, IPA seeks to enhance U.S.-India supply chain resiliency through strategic partnerships. This initiative aims to secure a reliable and robust supply chain that supports both nations' healthcare systems amidst global uncertainties. Additionally, IPA is dedicated to advancing sustainable reform measures to ensure the long-term affordability and availability of medicine. By advocating for these critical areas, IPA reinforces its commitment to improving healthcare outcomes and industry sustainability, ultimately benefiting patients in both the U.S. and globally.","lobbyists":[{"lobbyist":{"id":146416,"prefix":null,"prefix_display":null,"first_name":"KATHLEEN","nickname":null,"middle_name":null,"last_name":"JAEGER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":64,"name":"Federal Trade Commission (FTC)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"},{"id":39,"name":"State, Dept of (DOS)"},{"id":41,"name":"Treasury, Dept of"},{"id":22,"name":"U.S. Trade Representative (USTR)"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Indian Pharmaceutical Alliance is a trade association in India, representing key innovative and affordable medicine manufacturers. These manufacturers supply nearly 50% of Medicare Prescriptions, and of the top 10 U.S. therapeutic categories, the companies supply more than half of the prescriptions for 5 of the top 10 categories-ranging up to 60%. IPA members seek to explore U.S. - India supply chain resiliency partnership, and address affordable medicine sustainability reform measures.","foreign_entity_issues":"The Indian Pharmaceutical Alliance (IPA) is a trade association representing leading global manufacturers of innovative and affordable medicine. In lights of the current global supply chain vulnerabilities, particularly the dependence on China for the majority of Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), IPA is actively seeking to forge a U.S.-India affordable medicine supply chain resiliency partnership. Such a strategic initiative aims to address national security concerns and reduce dependency on a single source for critical generic pharmaceutical components. By enhancing U.S.-India collaboration, IPA aims to establish a more diversified and secure supply chain that supports the steady and reliable production of affordable medicines. This partnership not only promises to bolster national security of both nations but also ensures that they are better prepared to handle health crises by ensuring access to everyday medications.","lobbyists":[{"lobbyist":{"id":146416,"prefix":null,"prefix_display":null,"first_name":"KATHLEEN","nickname":null,"middle_name":null,"last_name":"JAEGER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":16,"name":"Natl Security Council (NSC)"},{"id":1,"name":"SENATE"},{"id":39,"name":"State, Dept of (DOS)"},{"id":22,"name":"U.S. Trade Representative (USTR)"},{"id":12,"name":"White House Office"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}